Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Treatment of acute stroke is still difficult and the only specific drug approved (rtPA) can
only be administered if treatment starts within 3 hours after onset of symptoms. This results
in a still too small number of patients treated with rtPA ( < 15% in best clinical care
institutions ). Ancrod is a differently acting biological drug which has been used for a long
time but not for acute stroke treatment. STAT was the first RCT of medium size to show a
significant benefit/risk ration if treatment starts within 3 hours. ESTAT was designed
closely related to STAT but with a longer 6 hours window and specifically extended
inclusion/exclusion criteria to avoid secondary complications possibly related to a longer
time window.